Loading...
NPI 1568542108 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Oscar Goodman is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 67 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Oscar Goodman |
| Address | 9280 W Sunset Rd Ste 100 |
| City | Las Vegas |
| State | NV |
| ZIP | 89148 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | October 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.4M |
| Medicaid | $11.4K |
This provider is effectively Medicare-focused: reported lifetime Medicare revenue is $1.4M versus $11.4K in Medicaid, so Medicare accounts for the overwhelming share of billed dollars and the practice’s scale is concentrated in the Medicare population. Medicaid activity is minimal in absolute terms and does not meaningfully diversify the payer mix.
Medicare revenue is highly concentrated in a small number of items: the top 3 Medicare codes by revenue account for 81.5% of this provider's total Medicare revenue, led by J9271, 99214, and J0881. That mix—an oncology drug (J9271), high-volume office E/M (99214), and an erythropoiesis-stimulating agent (J0881)—is consistent with a hematology/oncology practice that combines in‑office infusion/oncologic drug administration with frequent established-patient visits.
J9271 is the dominant single driver of Medicare dollars: it generated $920.7K (68.4% of Medicare revenue) and the provider ranks #326 of 1841 nationally (82th percentile; typical, unremarkable volume for this code). The absolute share shows pembrolizumab use is the primary revenue engine for this provider’s Medicare book, even though the provider’s national rank on the code is characterized as typical rather than exceptional.
The provider reports a very large national volume of established-patient office visits under 99214 on Medicare: 1.3K claims producing $124.9K (9.3% of Medicare revenue) and a national rank of #5819 of 479517 (99th percentile; extreme outlier). This label indicates the provider’s E/M visit volume is far above typical national peers and suggests a substantial established-patient clinic throughput or frequent follow-up visit pattern relative to other clinicians.
Billing patterns show an in‑office infusion and monitoring workflow: chemotherapy administration 96413 (342 claims, $35.9K) and add-on infusion 96417 appear among the top Medicare codes, and routine lab panels (80053, 85025, 36415) are also prominent. These codes together indicate the practice performs onsite chemo/infusion procedures and laboratory monitoring rather than relying exclusively on external infusion centers or labs.
Medicaid revenue is extremely concentrated and small: the top 3 Medicaid codes by revenue account for 98.8% of the provider's total Medicaid revenue, with 99214 ($7.8K, 68.7%) and 99213 ($3.1K, 27.6%) driving nearly all Medicaid billing. In‑state ranks for those codes are low–moderate (99214 rank #1650 of 2254, 26th percentile; 99213 rank #2024 of 2476, 18th percentile), indicating a modest Medicaid footprint and limited competitive standing in the state Medicaid market.
Competitive standing is mixed across payers and services: for Medicare this provider is a major revenue generator due to a single high-value drug (J9271) and an extreme outlier for 99214 office visits, while other drug and infusion codes (J0881, 96413) are in typical percentiles. For Medicaid the provider is a small participant statewide, with most Medicaid activity concentrated in routine office visits rather than high-cost drug infusion.
The provider has a long tenure in the dataset (NPI enumerated 2006-10-17 (~20 years ago)), consistent with an established oncology practice and an experienced patient panel; combined with the high concentration of Medicare revenue in a few codes, this suggests the practice’s revenue profile is sensitive to changes in utilization or reimbursement for those specific drugs and visit types.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
67 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 21,410 | $40 | $920.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,290 | $100 | $124.9K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 25,220 | $1 | $50.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 340 | $110 | $35.9K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 260 | $130 | $34.3K |
| J0897 | Injection, denosumab, 1 mg | 1,560 | $20 | $28.1K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 170 | $140 | $24K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 1,430 | $10 | $14.3K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 1,650 | $10 | $13.2K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 1,610 | $10 | $12.9K |
Showing 1–10 of 67
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
67 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 6 | 40 | 13,000 | $40 | $625.8K |
| J0897 | 56 | 70 | 3,630 | $20 | $94.6K |
| J0881 | 11 | 30 | 17,400 | $1 | $49.5K |
| J9217 | 8 | 40 | 120 | $130 | $23.9K |
| 96413 | 19 | 70 | 210 | $100 | $23.7K |
| 99232 | 812 | 1,340 | 140 | $60 | $23.7K |
| 84443 | 15 | 80 | 50 | $20 | $22.7K |
| 80053 | 10 | 100 | 160 | $10 | $22.2K |
| 99214 | 56 | 3,610 | 110 | $80 | $19K |
| 99223 | 1,025 | 1,280 | 60 | $130 | $13.7K |
Showing 1–10 of 67
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 80 | $90 | $7.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 50 | $60 | $3.1K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 40 | $10 | $280 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 10 | $10 | $140 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,650 | 2,250 | 290 | $60 | $138K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,024 | 2,480 | 330 | $50 | $107.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 119 | 130 | 1,600 | $1 | $74.9K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 139 | 160 | 1,190 | $1 | $39.8K |
Other providers in the same ZIP code as Oscar Goodman, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.